Myeloma Paper of the Day, June 2nd, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: DREAMM-7 study shows belantamab/bortezomib/dexamethasone superior to daratumumab/bortezomib/dexamethasone in RRMM with 1+ prior line, with median PFS 36.6 (vs. 13.4) months, OS at 18 months 84% vs. 73%, higher CR/MRD-neg rate, but more ocular events (79% vs. 29%).”
Source: Robert Orlowski/X
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Authors: V. Hungria, P. Robak, M. Hus, V. Zherebtsova, C. Ward, P.J. Ho, A.C. Ribas de Almeida, R. Hajek, K. Kim, S. Grosicki, H. Sia, A. Bryant, M. Pitombeira de Lacerda, G. Aparecida Martinez, A.M. Sureda Balarí, I. Sandhu, C. Cerchione, P. Ganly, M. Dimopoulos, C. Fu, M. Garg, A.-O. Abdallah, A. Oriol, M.E. Gatt, M. Cavo, R. Rifkin, T. Fujisaki, M. Mielnik, N. Pirooz, A. McKeown, S. McNamara, X. Zhou, M. Nichols, E. Lewis, R. Rogers, H. Baig, L. Eccersley, S. Roy-Ghanta, J. Opalinska, and M.-V. Mateos.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
